Bispecific Antibodies
With blockbuster deals by 3SBio, BioNTech, and Akeso, emerging Chinese PD-1/VEGF bispecifics like RC148, HB0025, JS207, and CS2009 are primed for billion-dollar licensing opportunities.
Ivonescimab
Akeso’s Ivonescimab achieves pivotal OS milestone in EGFR-mutant NSCLC, outperforming Keytruda and cementing its role in the PD-1/VEGF bispecific market.
China biopharma
A decade of transformation in China’s biopharma industry: first-in-class drugs, expanded clinical pipelines, R&D talent, and billion-dollar global partnerships reshaping pharma leadership.
Outbound Deals
Witness the new era of global biotech collaboration as China's top outbound deals inject billions into innovation. From 3SBio's $1.25B Pfizer licensing to BioNTech's acquisition of Biotheus, explore key themes in bispecifics, ADCs, and strategic partnerships.
Bispecific Antibodies
Bispecific antibodies are reshaping oncology and beyond. By 2025, 20 products are approved, with 2024 sales topping $126.5B led by Hemlibra and Vabysmo. China leads the pipeline with 35+ trials, two domestic approvals, and global partnerships.
BeOne Medicines
In a strategic move, BeOne monetizes its ex-China royalty stream for the DLL3×CD3 bispecific IMDELLTRA®, freeing capital for its pipeline while retaining domestic commercialization rights.
First-Time Disclosures
ACS Fall 2025 revealed 13 first-time clinical candidates across infectious disease, immunology, cardiometabolic, neurodegeneration, and oncology. This post reviews their targets, modalities, and competitive positioning—including China-based pipelines.
CDK4/6 inhibitors
With 9 CDK4/6 approvals and over 20 palbociclib generics, China’s oncology market is entering a phase of intense competition and price erosion. Meanwhile, the U.S. market stays concentrated under palbociclib, ribociclib, and abemaciclib, where strong patents keep generics at bay.
AI protein design
GPT-4b micro generates synthetic transcription factors that outperform traditional Yamanaka factors, marking a milestone in regenerative and longevity research.
H1 2025 earnings
H1 2025 earnings show Chinese pharma entering a new growth phase, led by oncology innovation, biologics, and international licensing deals. Global pharma maintains steady expansion via obesity, diabetes, and oncology blockbusters.
Tocilizumab Biosimilar
Chinese biotech Bio‑Thera partners with STADA to commercialize BAT1806, a tocilizumab biosimilar, in Europe, UK, Switzerland, MENA, and CIS regions. The deal reinforces Bio‑Thera’s international growth strategy and biosimilar pipeline.
Gumokimab
Akeso’s Gumokimab (AK111) achieves pivotal Phase III success in AS, complementing its non-oncology portfolio and boosting potential for domestic market share and future international licensing deals.